Top View
- Therapeutic Drug Class
- TASMAR® (Tolcapone) TABLETS
- Parkinson's Disease Medications
- Medications Approved for the Treatment of Parkinson's Disease In
- Practical Guidelines for Management of Parkinson Disease
- The Effect of Nicotine in Combination with Various Dopaminergic Drugs on Nigrostriatal Dopamine in Rats
- Psychopharmacologic Approaches to Attention, Alertness, and Initiation After Brain Injury Mel B
- Medication Glossary- Drug Classes and Medication
- Entacapone Is Beneficial in Both Fluctuating and Non-Fluctuating
- A Treatment Guide to Parkinson's Disease
- Tasmar, INN-Tolcapone
- New Zealand Data Sheet Tasmar®
- Drug Benefit Guide
- Medical Management of Parkinson's Disease
- LMMG New Medicine Recommendation
- Medical Necessity Criteria for Pharmacy Edits, 5.01.605
- Inbrija (Levodopa) Nourianz (Istradefylline) Effective 09/01/2020
- XADAGO™ (Safinamide) Oral
- COMT Inhibitors
- Download Product Insert (PDF)
- Benadryl Allergy/Cold: Indications, Side Effects, Warnings Drugs.Com
- Spotlight on Parkinson's Disease: What's New in Pd
- Dopamine Agonist Initiating Therapy in Early PD Patients: When Do We Initiate Therapy?
- AHFS Pharmacologic-Therapeutic Classification System
- The Ins and Outs of PD Meds Johanna Hartlein, APRN, MSN Family Nurse Practitoner and Great Hugger Washington University School of Medicine Words of Caution
- Opicapone: from Preclinical Data to Real-World Evidence
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- Supplementary Material
- Drug Discovery for Neurological Disorders: a Focus on Bioassay Development
- Opicapone for Parkinson's Disease
- Anti-PD Drugs
- COMT Inhibitors
- CP.PMN.113 Safinamide (Xadago)
- CCG Tolcapone Shared Care (Parkinson's) Guideline
- Inhibiting COMT in a Mouse Model of Parkinson's Disease: a Trial of Tolcapone in VMAT2-Deficient Mice
- UMP (Wsrxs) Preferred Drug List (PDL) 2021
- 212489Orig1s000
- Tasmar, INN-Tolcapone
- Orphan Drug Designations and Approvals List As of 03‐01‐2016 Governs April 1, 2016